Key points

  • Juniper Investment Company, LLC bought $5.11 million of Orthofix Medical Inc. stock in transactions dated November 11th, 2026. The purchases were reported across two Form 4 filings.
  • The firm picked up 689,803 shares. Reported prices ran from $7.0402 to $7.4111.
  • The buyer is an entity, filing in the "Other" insider role rather than as an officer or a director. That is the category used for ten percent owners and similar reporting persons.
  • Orthofix last traded at $6.94, below the range the firm paid. Market capitalization stands at $282,873,024.

Juniper Investment Company, LLC reported purchases of Orthofix Medical Inc. stock totaling $5.11 million, with transactions dated November 11th, 2026. The buying came to 689,803 shares and was disclosed through two separate Form 4 filings.

Orthofix Medical Inc. trades under the ticker OFIX and sits in the Surgical and Medical Instruments and Apparatus sector. The company carries a market capitalization of $282,873,024, which makes a purchase of this size meaningful against the float of the issuer rather than a routine odd lot.

What the filing shows

The reported transaction date on both filings is November 11th, 2026. Prices on the reported lines span $7.0402 to $7.4111, a tight band that is consistent with open market execution rather than a single negotiated block at one fixed price.

The filer is an institution, not an individual. Juniper Investment Company, LLC is listed in the "Other" role, the designation Form 4 uses for reporting persons who are neither officers nor directors, most commonly beneficial owners above the ten percent threshold. Nothing in the filings explains motive, and this article does not infer one.

What the firm paid

The arithmetic that matters here is simple. The firm committed $5.11 million for 689,803 shares at prices between $7.0402 and $7.4111. Two filings covering a single transaction date usually means more than one account or more than one reporting line rolled into the same disclosure obligation.

Institutional insider buying reads differently from an officer purchase. An officer or a director is buying with personal money and is subject to a narrower trading window. An entity in the "Other" category is typically running a position, and additions can be part of a larger program that has already been disclosed elsewhere. The one thing the Form 4 record establishes cleanly is size, price and date.

Where the stock sits

Orthofix last traded at $6.94. That is below the $7.0402 to $7.4111 band the firm reported paying, so the position is underwater against the reported purchase prices as of the last price in our table.

Readers should weigh that against the nature of the buyer. A firm accumulating a stake over time is not marking a single day's entry price the way a trader would. Still, for anyone tracking whether insider purchases are being validated by the tape, the last price is the relevant check, and here it sits under the range.

What that leaves

Three facts carry the story. The size is $5.11 million, the count is 689,803 shares, and the buyer is an institution rather than a named executive. Those three together put the purchase in a different bucket from the small, symbolic director buys that fill most Form 4 screens.

What the filings do not show is just as important. There is no stated reason for the purchase, no indication of whether more buying followed, and no disclosure in these two filings about the firm's total resulting position beyond what the forms themselves report. Any conclusion about intent would go past the document.

Orthofix operates in the Surgical and Medical Instruments and Apparatus sector, where company valuations often move on product approvals, reimbursement decisions and surgical volume trends. A market capitalization of $282,873,024 places the issuer at the smaller end of that group, which is the context in which a $5.11 million purchase registers as a real line item rather than background noise.

For investors following OFIX, the practical takeaway is narrow. An institutional insider filer paid between $7.0402 and $7.4111 on November 11th, 2026, for 689,803 shares, and the stock has since been quoted at $6.94. Everything else about the position remains outside the four corners of these filings.

Sources: SEC Form 4 filings submitted via EDGAR and reviewed by InsiderBuying.com, covering transactions dated November 11th, 2026.

Informational only, not investment advice.